Life Science and Technology Park
1951 NW 7th Avenue Suite 520
Miami, FL 33136
United States
305 909 0840
https://longeveron.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 23
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer & Chairman | 74k | N/A | 1963 |
Mr. Mohamed Wa'el Ahmed Hashad | CEO & Director | 781.56k | N/A | 1962 |
Ms. Lisa A. Locklear M.B.A. | Executive VP & CFO | 248.38k | N/A | 1962 |
Mr. Paul T. Lehr J.D. | International Executive Director, General Counsel & Secretary | 554.05k | N/A | 1968 |
Dr. Dan Gincel Ph.D. | Senior Vice President of Strategic Collaborations & Scientific Affairs | N/A | N/A | 1971 |
Dr. Nataliya Agafanova M.D. | Chief Medical Officer | N/A | N/A | 1970 |
Ms. Elly Ryu | VP & Corporate Controller | N/A | N/A | 1982 |
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Longeveron Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.